Please assess the completion status of the following clinical trial:

Trial Title: Outpatient Cervical Ripening With Orally Administered Misoprostol in Diabetics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Singleton gestation~2. Intact membranes~3. Bishop score \<= 4~4. Uterine contractions \<=12/hour~5. Cephalic presentation~6. Estimated gestational age of at least 38 weeks by ACOG dates~7. An amniotic fluid index (AFI) \>5 cm~8. Reactive Non Stress Test~9. Class A1, A2 diabetes~10. Good compliance with clinic visits and home glucose monitoring~Exclusion Criteria:~I. Fetal Factors~1. Multiple Gestation~2. Presence of fetal distress/non-reassuring FHR pattern~3. Malpresentation, including breech~4. EFW \> 4500 gm or other evidence of cephalo-pelvic disproportion~5. EFW \< 2000 gm~II. Maternal Factors~1. Frequent uterine contractions \>= 12/hour~2. Ruptured membranes~3. Placenta previa or unexplained vaginal bleeding~4. Vasa previa~5. Active herpes simplex~6. Glaucoma or elevated intraocular pressure~7. Renal or hepatic dysfunction~8. Previous Cesarean delivery or history of uterine surgery~9. Evidence of chorioamnionitis or maternal fetal \>= 100.4 degrees F~10. Significant cardiac lesion or cardiovascular disease~11. Severe asthma~12. Parity \>=6

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): patients will be treated with misoprostol 50 mcg PO
- 2 (Type: PLACEBO_COMPARATOR): patients will receive placebo (Vitamin C)

Based on this trial design, predict the completion outcome and termination type (if applicable).